Claims

1. Use of at least one inhibitor of polycationic aliphatic amine in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis.

2. The use of claim 1, wherein the subject is suffering from darkening of the skin and/or melanogenesis associated with pregnancy, inflammation, yeast infection, or aging.

3. The use of claim 1, wherein the at least one inhibitor of polycationic aliphatic amine is selected from the group consisting of: an inhibitor of the transport of polycationic aliphatic amine, an inhibitor of the synthesis of polycationic aliphatic amine, an inhibitor of the catabolism of polycationic aliphatic amine, and combinations thereof.

4. The use of claim 3, wherein the inhibitor of the transport of polycationic aliphatic amine is trimer44NMe.

5. The use of claim 3, wherein the inhibitor of the synthesis of polycationic aliphatic amine is difluoromethylornithine (DFMO).

6. The use of claim 1, wherein the at least one inhibitor of polycationic aliphatic amine is to be administered in a pharmaceutical composition.

7. The use of claim 6, wherein the pharmaceutical composition is provided as pastes, powders, dressings, creams, plasters, solutions, patches, gels, suspensions, aqueous liquid suspensions, non-aqueous liquid suspensions, oil-in-water emulsions, water-in-oil liquid emulsions, solutions, sterile solids, crystalline solids, amorphous solids, solids for reconstitution or combinations thereof.

8. The use of claim 6, wherein the pharmaceutical composition is a dermatological composition.

9. The use of claim 6, wherein the pharmaceutical composition is to be administered intradermally, cutaneously, subcutaneously, topically, transdermally, or any combination thereof.

10. The use of claim 2, wherein the subject is suffering from melasma.

11. The use of claim 2, wherein the subject is suffering from post inflammatory hyperpigmentation.

12. The use of claim 2, wherein the subject is suffering from solar lentigo.

13. The use of claim 3, wherein the inhibitor of the synthesis of polycationic aliphatic amine is an ornithine decarboxylase 1 (ODC1) inhibitor.

14. Use of at least one ornithine decarboxylase 1 (ODC1) inhibitor in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis, wherein the medicament is to be administered to a subject in need thereof, wherein the subject is suffering from melasma, post inflammatory hyperpigmentation, or solar lentigo.

15. The use of claim 14, wherein the subject is suffering from melasma.

16. Use of a difluoromethylornithine (DFMO) in the manufacture of a medicament for reducing darkening of the skin and/or melanogenesis, wherein the medicament is to be administered to a subject in need thereof, wherein the subject is suffering from melasma, post inflammatory hyperpigmentation, or solar lentigo.

17. The use of claim 16, wherein the subject is suffering from melasma.

18. A cosmetic method of reducing darkening of the skin and/or melanogenesis, the method comprising administering at least one inhibitor of polycationic aliphatic amine in a pharmaceutically effective amount to a subject in need thereof.